0 results for 'Boehringer Ingelheim'
Litigators of the Week: A Compassionate—But Effective—Product Liability Defense
When Boehringer Ingelheim was hit with a new wave of suits over its blood thinner Pradaxa, it changed course and decided to fight, tapping Covington & Burling's Phyllis Jones and Butler Snow's Rod Richmond Sr.Merck & Co. Names Covington's Jennifer Zachary as New General Counsel
A partner in Covington & Burling's food, drug, and device practice group and a former associate chief counsel for enforcement in the U.S. Food and Drug Administration's Office of Chief Counsel is named GC at the pharmaceutical giant.Pulling the Occasional 'All-Nighter,' Sidley Austin's Heidi Levine Is a Legal Machine
"I keep my calendar up-to-date every day. If it's not on my calendar, it doesn't exist in my life."Gross Revenue, Profits Per Partner Hit New Highs at Paul Hastings
The firm's top line grew for the sixth consecutive year, to $1.12 billion, while profits per partner jumped nearly 12 percent to $2.9 million.Revenue and PEP hit new heights at Paul Hastings as US firm posts 25% London growth
O'Melveny breaks $2m PEP mark for first time as Baker Botts sees double-digit revenue dipFTC Nominee Christine Wilson Discloses Her In-House Earnings at Delta
New financial disclosure documents provide insight into the pay and assets of the Delta senior vice president for legal, regulatory and international.Skilled in the Art: These Patent Lawyers Had a Pretty Great Week. Plus Celebs and Copyrights
Notable wins for Ed Reines of Weil, Gotshal & Manges and Santa Monica's Kayvan Noroozi, and Peter Perkowski of L.A.'s Perkowski Legal sues singer and actress Jessica Simpson for infringing the copyright on photos of herself.Skilled in the Art: Is PTAB Asking for 'Oil States' Trouble With Ruling on Sovereign Immunity?
By analogizing IPRs to district court litigation, a Patent Trial and Appeal Board panel led by Chief Judge David Ruschke just undercut its position in its Supreme Court fight for survival.NJ to Get $287K Share of Boehringer's $13.5M Off-Label Marketing Settlement
Boehringer Ingelheim Pharmaceuticals Inc. will pay $13.5 million to settle allegations by attorneys general in all 50 states and the District of Columbia that the company marketed some of its drugs for unapproved uses.Boehringer to Pay $13.5M to Settle States' Off-Label Marketing Claims
Boehringer Ingelheim Pharmaceuticals Inc. will pay $13.5 million to settle allegations by attorneys general in all 50 states and the District of Columbia that the company marketed some of its drugs for unapproved uses.State AI Legislation Is on the Move in 2024
Brought to you by LexisNexis®
Download Now
2024 ESI Risk Management & Litigation Readiness Report
Brought to you by Pagefreezer
Download Now
Creating a Culture of Compliance
Brought to you by Ironclad
Download Now
A Buyer's Guide to Law Firm Software
Brought to you by PracticePanther
Download Now